By Zeba Siddiqui MUMBAI (Reuters) – India’s second-largest drugmaker Dr Reddy’s Laboratories Ltd said it agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350 million in cash to bolster its U.S. business. The deal is among Dr Reddy’s biggest acquisitions, and comes at a time when the company has been facing slowing growth in the United States, its largest market, due to regulatory troubles and fewer new drug approvals. The drugs Dr Reddy’s is buying are being divested by Israel-based Teva, the world’s largest maker of generic drugs, to win U.S. antitrust clearance for its $40.5 billion acquisition of Allergan’s generic drugs portfolio.
View original post here:
India’s Dr Reddy’s in $350 million deal to buy eight U.S. drugs from Teva, Allergan